For years, oncologists have leaned on a variety of chemotherapies to battle cancer. They could use these versatile agents to battle multiple types of cancer, from non-Hodgkin lymphoma to colorectal cancer.
Now, a new wave of immunotherapy agents is sweeping the cancer landscape and offering hope and excitement across a similarly diverse set of tumor types. Some platforms are ambitious: One therapy is claiming to launch 50-plus indications. In totality, marketed products with multiple indications are expected to increase by more than 40% by 2020, according to the Office of Health Economics. These new entries are set to join increasingly crowded spaces, amplifying the need for a careful, differentiated strategy.Read More